A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Phase 1
542
about 7 years
18+
30 sites in AL, AZ, CA +14
What this study is about
This trial is testing different treatments, including drugs and immunotherapy, to see if they are safe and effective for people with advanced colorectal cancer whose tumors have specific biomarkers. Participants will be assigned to treatment arms based on their biomarker results.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.FoundationOne®Liquid CDx
- 2.Take Atezolizumab
- 3.Take Bevacizumab
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
atezolizumab, bevacizumab, cetuximab, Antineoplastic Agent [TC] (Phosphoinositide 3-Kinase alpha Inhibitors), monoclonal antibody
injection (Injection), infusion, oral (Oral Tablet)
Primary: Objective Response Rate
Secondary: Disease Control Rate, Duration of Response, Percentage of Participants with Adverse Events (AEs)
Oncology